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Plasmodium vivax poses unique challenges for malaria control and elimination, notably the
potential for relapses to maintain transmission in the face of drug-based treatment and vector
control strategies. We developed an individual-based mathematical model of P. vivax
transmission calibrated to epidemiological data from Papua New Guinea (PNG). In many
settings in PNG, increasing bed net coverage is predicted to reduce transmission to less than
0.1% prevalence by light microscopy, however there is substantial risk of rebounds in
transmission if interventions are removed prematurely. In several high transmission settings,
model simulations predict that combinations of existing interventions are not sufﬁcient to
interrupt P. vivax transmission. This analysis highlights the potential options for the future of
P. vivax control: maintaining existing public health gains by keeping transmission suppressed
through indeﬁnite distribution of interventions; or continued development of strategies based
on existing and new interventions to push for further reduction and towards elimination.
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Renewed scientiﬁc and ﬁnancial commitment to controllingand eliminating malaria has led to reductions in globalmalaria cases by 37% and reductions in malaria associated
deaths by 60% since 20001. Although the greatest public health
burden is attributable to Plasmodium falciparum, predominantly
in children and pregnant women in sub-Saharan Africa, it is
increasingly recognised that P. vivax may pose a greater challenge
to malaria elimination efforts2. For countries with co-endemic P.
falciparum and P. vivax, it has been repeatedly observed that as
the total malaria burden decreases, the proportion of cases
attributable to P. vivax increases3. The major obstacle to P. vivax
elimination is its ability to relapse from dormant liver-stage
hypnozoites, weeks to years after clearance of the primary blood-
stage infection4.
The highest levels of P. vivax transmission in the world are
found in Papua New Guinea (PNG)5, with parasite prevalence by
light microscopy (PvPRLM) in excess of 10% frequently reported6.
PNG has a wide diversity of P. vivax transmission settings, with
large variations in altitude, many different mosquito species, and
varying levels of co-endemicity with P. falciparum7. PNG has also
made some of the most signiﬁcant contributions to the global
understanding of P. vivax transmission and control, ranging from
clinical trials to assess the effectiveness of artemisinin combina-
tion therapies (ACT)8,9, to the demonstration that ~80% of new
blood-stage infections are attributable to relapses10. PNG there-
fore provides an excellent case study for modelling the impact of
combinations of interventions on P. vivax across a wide range of
transmission settings, providing valuable lessons that can be
applied in any P. vivax endemic setting.
The two pillars of malaria control in PNG are treatment of
symptomatic cases and vector control. National treatment pro-
tocols recommend ﬁrst-line treatment of uncomplicated malaria
due to all species of malaria with artemether-lumefantrine (AL),
plus primaquine for cases that are positive for either P. vivax or P.
ovale. Access to rapid diagnostic tests (RDTs) and treatment with
AL are available in ~50% of ﬁrst-line health centres or aid posts,
with primaquine availability being much more limited11. From
2005 the PNG National Malaria Control Programme, supported
by the Global Fund, has overseen nationwide, free distribution of
long-lasting insecticidal nets (LLIN)12. These LLIN distributions
have coincided with major reductions in malaria transmission,
with P. falciparum prevalence by light microscopy (PfPRLM) and
PvPRLM reducing nationwide by 20–99% between 2009 and 2014,
with P. vivax initially decreasing more slowly than P.
falciparum13,14. The relative contributions made by LLINs and
ACTs in the reduction of malaria prevalence in PNG are
unknown, but it is likely that LLINs are the larger contributor, in
line with ﬁndings from an analysis of P. falciparum in Africa15.
ACTs are very effective for treating uncomplicated and severe
episodes of P. vivax16, but are unlikely to cause substantial
reductions in onward transmission unless treatment is accom-
panied with primaquine to prevent relapses.
It is not possible to directly detect P. vivax hypnozoites with
existing technology, and they can be cleared by treatment with
just one class of drug, the 8-aminoquinolines (8-AQ). Primaquine
is the only licensed 8-AQ, but it requires a lengthy
treatment regimen and risks causing episodes of severe haemo-
lysis in glucose-6-phosphate-dehydrogenase (G6PD) deﬁcient
individuals17,18. To mitigate against this risk, it has been advised
that primaquine be delivered alongside testing for G6PD deﬁ-
ciency19. Screening for G6PD deﬁciency is not routinely available
in developing countries such as PNG, although point-of-care
G6PD diagnostics are becoming available in some settings20. The
effectiveness of primaquine is often diminished because of chal-
lenges in adhering to long treatment regimens21 and poor efﬁcacy
in individuals with low CYP2D6 metabolizer phenotypes22.
Another 8-AQ, tafenoquine, is currently undergoing clinical trials
and promises to have comparable efﬁcacy with a single dose23.
However, tafenoquine may also cause haemolysis in G6PD deﬁ-
cient individuals, so its use will be contingent on effective G6PD
screening.
Although there is evidence for the role played by vector control
in reducing levels of P. vivax, there is no strong evidence base for
the potential impact of widespread treatment with primaquine or
tafenoquine on reducing population-level transmission in coun-
tries with high levels of transmission of tropical strains of P.
vivax. Mathematical models can provide key insights into how
treatment strategies may affect P. vivax transmission. For exam-
ple, Robinson et al10. highlighted that a mass drug administration
(MDA) programme with primaquine and G6PD testing may
cause substantial reductions in transmission, but that a mass
screen and treat (MSAT) programme with parasitological
screening (with either RDTs or PCR) is unlikely to be effective
because of the inability to detect hypnozoites. Substantial ques-
tions remain about the potential impact of increasing access to
anti-hypnozoite drugs for ﬁrst-line treatment of all symptomatic
cases, or if adding MDA rounds to our current set of control tools
can help accelerate towards elimination. Assessing the impact of
these intervention strategies on population-level transmission will
require large, well-designed intervention trials or detailed obser-
vational studies. In the interim when such data are not available,
mathematical models will play a key role allowing estimation of
the effect size of interventions and aiding the design of future
population-level intervention studies.
Here, we build on existing theoretical methods for the con-
tribution of relapses to P. vivax transmission24–29, and develop a
new, detailed individual-based simulation model of P. vivax
transmission calibrated to data from many epidemiological stu-
dies from PNG and the Solomon Islands. Using this simulation
model we investigate the impact of current and future malaria
control interventions on P. vivax, and the potential impact of
future treatment strategies with primaquine or tafenoquine.
Results
Model calibration to epidemiological data. The model captures
the key features of the epidemiology of P. vivax observed in
multiple cross-sectional and longitudinal studies (Table 1), most
notably the distinctive peaks in prevalence and clinical incidence
in children younger than 10 years of age (Fig. 1). Although the
model accurately captures the PvPRLM peak, the PvPRPCR peak is
not fully captured. The data and model demonstrate a consistent
ordering in the timing of these peaks, with clinical incidence
peaking in the youngest age groups, followed by PvPRLM, and
then by PvPRPCR. In higher transmission settings, there is a
notable shift of the peaks to younger age groups.
Model validation. The results presented in Fig. 1 demonstrate
that the model captures some key features of P. vivax epide-
miology in PNG. However, as the model was explicitly calibrated
to these datasets, it may be susceptible to a degree of overﬁtting.
To demonstrate applicability of the model beyond PNG, we
compared the model-predicted relationships between P. vivax
prevalence, entomological inoculation rate (EIR), clinical inci-
dence and hypnozoite prevalence to data from systematic reviews
from P. vivax studies from across the world with varying age
ranges30,31 (Fig. 2). Although there are standardised methods for
measuring P. vivax prevalence, estimates of clinical incidence can
be very variable according to whether surveillance is undertaken
by passive case detection (PCD) or active case detection (ACD)
and the frequency of ACD. In particular, more intense ACD will
yield higher estimates of P. vivax incidence in the same setting30.
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Table 1 Data from cross-sectional and longitudinal studies used for model calibration
Location Study period Age (years) PCR LM Clinical Reference
Cross-sectional data
Ngella, Solomon Islands 2012 18 (0.5, 100) 468/3501 127/3501 15/3501 Waltmann61
PNG; >1500m 2000/02 16 (0.4, 77) 32/664 5/664 Senn62
PNG; 1000–1500m 17 (0.6, 95) 217/2835 35/2835 Senn62
PNG; 500–1000m 19 (0.0, 87) 446/9030 93/9030 Senn62
PNG; 0–500m 22 (0.1, 99) 290/9943 109/9943 Senn62
Wosera, East Sepik 1991/92, 1998/99, 2001/03 17 (0.1, 80) 901/2527 368/2527 24/2527 Mueller63
Wosera, East Sepik 1991/92 17.4 (0.1, 87) 1207/6782 Genton64
Wosera, East Sepik 2001/03 17 (0.1, 99) 1639/15737 Kasehagen65
Madang 2006 14.2 (0.0, 72) 204/1227 22/1227 Koepﬂi66
Ilaita & Sunuhu 2006 1.7 (0.8, 3.2) 1433/2129 1092/2129 133/2129 Lin67
Longitudinal data
Mugil, Madang 2004 9.3 (4.8, 14.4) 192/204 139/204 10/204 Michon68
Albinama, East Sepik (placebo arm) 2008/09 7.6 (4.8, 10.4) 179/257 132/257 22/257 Robinson10
Albinama, East Sepik (primaquine arm) 2008/09 7.5 (4.9, 10.4) 69/247 45/247 9/247 Robinson10
Wosera, East Sepik 1998/99 16 (0.1, 85) 686/1689 Kasehagen69
Age is presented as median with range. Samples were tested for parasitaemia by PCR or light microscopy, or for a clinical case of P. vivax if accompanied by fever in the last 48 h
n/N denotes n positive out of N samples
50%
1500+ m, N = 9943, (Senn)
Solomon Islands, N=3499, (Waltmann) Wosera, N=15,737, (Kasehagen) Madang, N=1227 Wosera, N=6782, (Genton)
East Sepik, N = 2129, (Lin)Wosera, N = 2527, (Mueller)
Placebo, N = 257, s = 3605 (Robinson) Primaquine, N = 247, s = 3551 (Robinson) Madang, N = 206, s = 2472 (Michon) Wosera, N = 1690, s = 6752 (Kasehagen)
1000–1500 m, N = 9030, (Senn) 500–1000 m, N = 2835, (Senn) 0–500 m, N = 664, (Senn)
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Fig. 1 Calibration of model to cross-sectional and longitudinal surveys from PNG and the Solomon Islands. For the cross-sectional surveys, the data are
presented as age-stratiﬁed estimates of prevalence with 95% conﬁdence intervals. The same deﬁnition of clinical malaria was used in all cross-sectional
surveys: high density parasitaemia and fever (≥38 °C) in the last 48 h. The number of individuals in each cross-section is denoted N. For the longitudinal
surveys in the bottom row, the data are presented as Kaplan–Meier estimates of proportion infected with 95% conﬁdence intervals. The number of
individuals included in longitudinal follow-up is denoted N and the total number of samples denoted s. The solid curves show the posterior median model
prediction, and the shaded regions denote the 95% credible intervals
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05860-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3300 | DOI: 10.1038/s41467-018-05860-8 | www.nature.com/naturecommunications 3
Simulation of intervention scenarios. Figure 3 shows past and
future projections of P. vivax in the provinces of PNG. The black
curves denote estimated PvPRLM based on provincial level data
from past LLIN distribution campaigns, under a scenario where
nets are not replaced (50% of nets are still in use after
19.5 months). In all situations, if LLIN campaigns do not con-
tinue, we predict there to be substantial rebounds in P. vivax—
exceeding even pre-intervention baselines. This rebound is attri-
butable to waning levels of immunity and the lack of acquisition
of immunity in young children born since 2009 after the reduc-
tion in P. vivax transmission. The stochastic uncertainty of this
rebound is shown in Supplementary Figures 12 and 13.
A range of future intervention scenarios are simulated. In a
situation where LLINs are distributed every 3 years at 50%
coverage, we predict that transmission can be reduced to <0.1%
PvPRLM in low transmission provinces. In provinces with
moderate transmission, we predict that transmission will remain
suppressed but not interrupted. In high transmission provinces we
predict that prevalence will slowly rebound over time. Increasing
coverage levels to 80% is predicted to prevent this rebound. Vector
control is predicted to be effective across all of PNG, however
impact is expected to be more limited in provinces with a high
proportion of outdoor and early biting Anopheles farauti s. s.
(predominantly coastal and island provinces such as New Britain
and New Ireland). The introduction of the 8-AQs primaquine or
tafenoquine into ﬁrst-line treatment regimens for symptomatic P.
vivax cases was simulated from 2020. This was projected to cause
further reductions in PvPRLM with the greatest reductions
expected in provinces where transmission remains high even
after the introduction of vector control.
As the assumptions regarding vector control are critical to the
model predictions, a number of sensitivity analyses were
performed. Assuming slower loss of LLIN adherence32,33 resulted
in marginally greater predicted reductions in P. vivax transmis-
sion (Supplementary Figures 9 and 10). A counterfactual scenario
was considered where LLINs were assumed not to be effective,
with the reductions in PvPRLM instead being attributable to a
massive scale up in primaquine treatment with screening for
G6PD deﬁciency from 2011 (Supplementary Figure 11). In such a
scenario, predicted reductions in PvPRLM were not consistent
with the magnitude of the observed reductions, suggesting that
the increases in LLIN coverage are attributable for the reductions
in P. vivax, in agreement with epidemiological studies13,14.
Provincial stratiﬁcation in Papua New Guinea. Figure 4a, b
shows PvPRLM across PNG in 2010 and 2014 based on household
prevalence surveys. Figure 4c shows projected PvPRLM in 2025 if
LLIN distribution campaigns at 80% coverage are maintained
every 3 years. Notably, we predict that in a large proportion of
mainland PNG, P. vivax will be suppressed to transmission levels
less than 0.1% PvPRLM. The most challenging areas consist of the
islands of New Britain, New Ireland and Bougainville, as well as
the coastal provinces of Sandaun and Milne Bay. All of these
provinces had high baseline levels of transmission as well as a
high proportion of An. farauti s. s. Fig. 4d shows the combination
of interventions required to reduce PvPRLM to less than 0.1% by
2025. It is assumed that LLIN coverage is ﬁrst scaled up, followed
by scaling up access to tafenoquine with screening for G6PD
deﬁciency in ﬁrst-line treatment regimens from 2020, and ﬁnally
a tafenoquine MDA with screening for G6PD deﬁciency at 80%
coverage in 2020. Detailed output of the simulations are
provided in Supplementary Figures 12–20. Although combina-
tions of interventions were projected to be sufﬁcient to obtain
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Fig. 2 Validation of model to data from systematic reviews. Data are shown as points and model predictions as solid lines. a Relationship between PvPRLM
and clinical incidence based on data reviewed by Battle et al.30. Studies included in this review came from throughout the world, had various age ranges,
and differences in the frequency of active case detection (ACD) for clinical cases of P. vivax. b Relationship between EIR and PvPRLM compared to data
reviewed by Battle et al. plus data from a study in Papua New Guinea by Burkot et al.60. Orange points denote studies where infectious mosquitoes were
conﬁrmed as P. vivax positive, and green points denote studies where mosquitoes were identiﬁed as infectious but without Plasmodium species
identiﬁcation. In some studies, a range was provided instead of a point estimate. c Relationship between PvPRLM and PvPRPCR compared to data reviewed
by Moreira et al.31. Data are from throughout the world and are based on studies with various age ranges. dModel-predicted relationship between PvPRLM
and hypnozoite prevalence. As it is currently not possible to directly detect hypnozoites, this relationship cannot be formally compared to any data
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PvPRLM < 0.1% in most provinces, there are several provinces
where we do not expect reduction in transmission to this level
(Fig. 4d).
Controlling P. vivax in high transmission settings. PNG con-
tains areas with the most intense P. vivax transmission in the
world5,6, which may pose some of the greatest challenges to
malaria elimination worldwide. Figure 5 presents model projec-
tions of P. vivax under a range of intervention scenarios in just
such a high transmission setting in New Ireland—an island
province with a high proportion of early biting An. farauti s. s.34.
Large reductions in P. vivax transmission are expected to be
achievable by scaling up LLIN coverage and access to tafenoquine
treatment, but we do not expect these interventions to be sufﬁ-
cient to interrupt transmission. Tafenoquine, administered
through either ﬁrst-line treatment or MDA campaigns, is pro-
jected to cause a 58–86% reduction in cases of P. vivax (Fig. 5e).
Notably, although MDA campaigns produce sharp reductions in
transmission they necessitate a large degree of over-treatment
(Fig. 5f), i.e. drugs given to individuals without any parasites.
Discussion
PNG is at a key stage in its journey towards controlling and
eliminating malaria, having achieved large reductions in P.
falciparum and P. vivax prevalence throughout the country fol-
lowing mass distribution of LLINs14. Despite this encouraging
progress, there are real risks of widespread rebounds, particularly
for P. vivax. Notably, following increased coverage of LLINs there
were large reductions, but not elimination, of both P. vivax and P.
falciparum in villages in Madang province, followed by a rebound
in P. vivax35 with more recent evidence suggesting a slower
rebound for P. falciparum. The reasons for this rebound are
unclear, but may be due to user fatigue with LLINs, stock-outs of
anti-malarial drugs, a shift of mosquito biting to early evening36
or waning population-level immunity. A key result of this analysis
is that if LLIN replacement does not continue, then P. vivax
rebounds will occur leading to higher levels of transmission than
before LLIN distribution. Those most at risk will be young chil-
dren born since 2009 who have grown up in times of low malaria
transmission. Rebounds have been repeatedly observed in over 60
countries, including the PNG highlands37,38 usually following
reductions in coverage of malaria control interventions. It is
therefore urgent that funding for continued nationwide LLIN
distribution be maintained.
Our second key result demonstrates that although maintaining
high levels of LLIN coverage will prevent rebounds, it will not be
sufﬁcient to eliminate P. vivax transmission in many provinces,
particularly areas with a large proportion of An. farauti s. s. Given
the unpalatable options of potentially catastrophic rebounds or
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Fig. 3 Predicted PvPRLM in Papua New Guinean provinces using individual-based model. Model predictions are based on the median of 100 stochastic
simulations. Data are from household prevalence surveys in randomly selected villages14, and surveys from a number of sentinel villages either before or
after LLIN distribution13. The black curves denote the model-predicted scenario if LLINs are not replaced. In the LLIN campaigns, nets are assumed to be
distributed every 3 years, with 50% of nets still in use after 19.5 months. Primaquine (PQ) or tafenoquine (TQ) with accompanying G6PD screening are
assumed to be include in ﬁrst-line treatment regimens from 2020, with 50% of individuals experiencing a clinical episode of P. vivax being tested and
treated
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indeﬁnite, expensive vector control, there is a strong case to
consider combinations of LLINs with new and existing inter-
ventions. First-line treatment of symptomatic malaria cases
through health centres and aid posts has long been a crucial
platform for delivering interventions in PNG39. Although pri-
maquine is available in some health facilities, there is little
available data on its routine use. The simulations presented here
demonstrate that increasing primaquine availability can cause
substantial reductions in transmission. However, these high
prevalence settings are not representative of the many settings in
these regions with low or epidemic P. vivax transmission, where it
will be important to identify the minimum level of malaria
control coverage interventions that can prevent transmission.
Two of the major barriers to effective primaquine treatment are
problems with adherence and dosing, and the failure to clear
hypnozoites in individuals with a low CYP2D6 metabolizer
phenotype22. Tafenoquine is not subject to these limitations,
although its single high dose means that it could not be provided
without G6PD screening. Phase 3 trials of tafenoquine have
recently been completed which will provide key data on efﬁcacy
in treated individuals, however there is an important need to
consider the impact on population-level P. vivax transmission.
Two key strategies are to increase availability of tafenoquine
treatment and G6PD testing in health facilities for ﬁrst-line
treatment of symptomatic episodes, or to presumptively treat
entire populations with MDA programmes. The expected effect
size will depend on several factors including transmission
intensity and the presence of other interventions. In the high
transmission setting modelled in Fig. 5, we predict that tafeno-
quine with screening for G6PD deﬁciency administered as part of
ﬁrst-line treatment or through MDA could cause a 58–86%
reduction in P. vivax cases. An important limitation of MDA
programmes with 8-AQs is that many people unlikely to have
hypnozoites end up receiving a potentially dangerous treatment
regimen. Such a degree of over-treatment has been acceptable in
past successful P. vivax elimination programmes based on MDA
with primaquine in China and former Soviet countries40,41 where
detailed population-level surveillance for side effects was possible.
However comparable campaigns have not taken place in resource
poor settings with intense transmission of tropical strains of P.
vivax.
Controlling and eliminating malaria requires addressing all
species, including P. ovale and P. malariae42. Although P. falci-
parum has long been seen as the primary contributor to the
public health burden of malaria, there is increasing evidence that
P. vivax is responsible for a comparable degree of mortality,
primarily due to high levels of anaemia in patients suffering from
multiple relapses43. Although a malaria control programme
designed with the aim of reducing P. falciparum transmission will
also succeed in reducing transmission of other Plasmodium spe-
cies, the fact that P. vivax begins to dominate as transmission is
reduced means that there is an important need to incorporate P.
vivax interventions aimed at tackling the hypnozoite reservoir.
There are a number of limitations to the model and analysis
presented here. Most notable is the choice of province as the
spatial transmission unit in PNG. These provinces are geo-
graphically large with sizable populations and considerable
diversity in malaria transmission. Highland provinces have very
variable transmission where pockets of high transmission persist
in valleys with lower altitude. Although we have used the best
epidemiological data currently available, the future strengthening
of health information systems in PNG will allow for a more
reﬁned approach with simulation of Districts or Local Level
Government areas44. Although a province as a whole may have
very low numbers of P. vivax cases, there may be sub-regions with
ongoing transmission. An improved understanding of spatial
heterogeneity would greatly aid targeted elimination efforts.
Inter-provincial travel is also likely to provide a barrier to
2010 prevalence surveys 2014 prevalence surveys
Intervention mix for pre-elimination by 20252025 model predictions with 80% LLIN coverage
0% 0.1% 0.2% 0.5% 2%1% 5% 10%
50% LLIN 80% LLIN
80% LLIN + 50% TQ 80% LLIN + 70% TQ 80% LLIN + 70% TQ + TQ MDA
80% LLIN + 30% TQ
Light-microscopy prevalence
a b
c d
Fig. 4 Predicted impact of combinations of interventions in Papua New Guinea. Model predictions are based on the median of 100 stochastic simulations.
a, b Estimated PvPRLM in Papua New Guinea provinces based on household surveys from 2010 and 2014. c Model-predicted prevalence in 2025 under a
scenario where LLINs are distributed every 3 years at 80% coverage levels. d Combinations of interventions required to obtain pre-elimination (deﬁned as
prevalence < 0.1%) by 2025. Grey shading indicates that the interventions considered were predicted not to be sufﬁcient to reduce prevalence to <0.1%
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elimination efforts, although additional simulations accounting
for travel did not produce substantially different estimates of the
impact of interventions in each province. The accuracy of pre-
dictions is further limited by the data available for model cali-
bration. Although there is very rich data on the epidemiology of
relapses and age-stratiﬁed prevalence and clinical incidence, there
are some key areas of uncertainty in our understanding of P.
vivax transmission. Chief amongst these is understanding the
contribution of low-density blood-stage infections to onwards
transmission to mosquitoes45, systematic differences in blood-
stage infections resulting from mosquito bites or relapses, and the
duration of naturally acquired immunity. Furthermore, we do not
account for the genetic diversity of P. vivax parasites, which
typically exhibits greater diversity than P. falciparum parasites in
co-endemic regions, suggesting that in comparison to P. falci-
parum, transmission of P. vivax is stable with a large effective
population size46,47.
The representation of mosquitoes in the model is by necessity a
simpliﬁed one. The three primary malaria vectors An. farauti s. s.,
An. punctulatus and An. koliensis are accounted for, however
there are many other species that likely play important roles in
sustaining transmission. For the three primary species, there was
detailed data from PNG and the Solomon Islands on key ento-
mological parameters such as the human blood index, biting
times and seasonality (reviewed in detail in Supplementary
Table 3). A key limitation is the absence of data from these
regions on mosquito interactions with LLINs, comparable to
measurements from experimental hut trials for African malaria
vectors48. More generally, a key challenge for vector control in P.
vivax endemic settings is the development of strategies for tar-
geting outdoor biting mosquitoes. This need may be met in the
future through the rapid adaptation of new interventions to target
outdoor biting being developed in Africa for species such as An.
arabiensis49.
The diversity of malaria transmission settings in PNG, ranging
from intense transmission in coastal areas to occasional epi-
demics in the Highlands, makes it an ideal case study for
understanding how combinations of malaria control interven-
tions can be used to control and eliminate P. vivax. Mathematical
models of the transmission cycle accounting for P. vivax relapses
provide an invaluable tool for exploring the potential impact of
existing and future intervention scenarios. Although the model
was calibrated against PNG data, its ﬁndings are still applicable to
other P. vivax endemic regions such as South East Asia and South
America after adjustments to account for local epidemiological
data. Further development and application of these models will
aid in the design of malaria control strategies with new inter-
ventions, and more critically outline what is achievable with
currently available interventions.
Methods
Mathematical model of P. vivax transmission. Ross-Macdonald mathematical
models of vector-borne disease transmission have previously been extended to
incorporate the relapses characteristic of P. vivax24,25. Here we build on these
methods to develop an individual-based simulation model of the transmission
dynamics of P. vivax using a comparable framework to existing models of P.
falciparum transmission50,51. This framework accounts for heterogeneity and
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seasonality of exposure to mosquito bites; detailed mosquito bionomics and
modelling of larval population densities; demographic age structure; exposure and
age-dependent acquisition of immunity against blood-stage infection and clinical
episodes; maternally-acquired immunity; and treatment of clinical cases and drug
prophylaxis. A key advantage of using an individual-based framework is the ability
to account for the complexity that arises when individuals have different combi-
nations of interventions, levels of immunity and genotypes52. Figure 6 shows a
compartmental representation of the model. Notably the infected state is ordered
according to whether an individual’s blood-stage infection is detectable by PCR
(IPCR), detectable by light microscopy (ILM) or whether they are undergoing a
clinical P. vivax episode (ID).
Relapses are described by two key epidemiological parameters: the relapse rate
(f) and the liver-clearance rate (γL). It is assumed that following an infectious
mosquito bite, the liver will remain infected with hypnozoites for an expected 1/γL
days, with a relapse occuring on average every 1/f days24. We allow for super-
infection with batches of hypnozoites originating from different mosquito bites. If
an individual has k batches of hyponozoites then relapses will occur at rate kf and
the number of batches will reduce from k to k − 1 at rate kγL until the liver has
been cleared of infection with hypnozoites.
Individuals acquire immunity at a rate proportional to the force of blood-stage
infection (with contributions from both new mosquito infections and relapses).
Two forms of immunity are accounted for: (i) anti-parasite immunity which
reduces the probability that a blood-stage infection will achieve sufﬁciently high
densities to become detectable by light microscopy and increases the rate of
clearance of blood-stage infection (Ap in Fig. 6); and (ii) clinical immunity which
reduces the probability that a blood-stage infection will progress to cause a case of
clinical malaria (Ac). Complete mathematical details of the model are provided in
the Supplementary Information.
The three most important malaria vectors in PNG are An. farauti s. s., An.
koliensis and An. punctulatus53. The population dynamics of these species are
modelled assuming density-dependent competition within seasonally varying larval
breeding sites54. The feeding, resting and oviposition behaviour of adult female
mosquitoes are described by a number of key entomological parameters including
life expectancy, human blood index (HBI), proportion of day time biting, and
indoor resting preferences. See Supplementary Table 3 for full details.
Model ﬁtting. The model was ﬁtted to age-stratiﬁed data on P. vivax prevalence by
PCR or light microscopy and clinical cases of P. vivax from 56,772 individuals from
11 cross-sectional or longitudinal studies from across PNG and the Solomon
Islands (Table 1). The parameters describing the transitions between human states
and the acquisition of immunity were estimated by ﬁtting the equilibrium solution
of the deterministic model to the data using Bayesian Markov Chain Monte Carlo
(MCMC) methods. All prior and posterior parameter estimates are provided in
Supplementary Table 2.
The impact of interventions was simulated using the stochastic, individual-
based implementation of the model with a population size of 100,000, initialised
using the equilibrium solution of the deterministic model. For every intervention
scenario considered, the model was run 100 times with results presented as the
median and 95% range of these simulations. The large population size resulted in a
limited range of stochastic variation55.
Intervention models: treatment. The existing malaria treatment guidelines in
PNG recommend that malaria cases conﬁrmed positive for P. vivax or P. ovale be
administered primaquine at 0.25 mg/kg for 14 days. Primaquine is sporadically
available across the country, there is no access to G6PD deﬁciency testing, and
levels of adherence are unknown11. The incorporation of the 8-AQs primaquine
and tafenoquine into ﬁrst-line treatment regimens was simulated in the model. The
full treatment pathways are provided in Supplementary Figure 5 and summarised
as follows. It was assumed that a 14-day primaquine treatment regimen has 70%
effectiveness at clearing hypnozoites (due to poor adherence), and that a single
dose of tafenoquine has 100% effectiveness against hypnozoites. Furthermore,
tafenoquine is assumed to provide 60 days of prophylaxis against further blood-
stage or liver-stage infections23. We assumed that 8-AQs were not given to preg-
nant women (about 4% of the population) or children under 6 months of age
(about 2.2% of the population). We further assumed that testing for G6PD deﬁ-
ciency was available, e.g. through a test similar to CareStart20. The G6PD allele
frequency in PNG was assumed to be qG6PD= 7.4%18. Therefore 0.5*qG6PD= 3.7%
of the population are G6PD deﬁcient males, 0.5*q2G6PD= 0.27% are G6PD
homozygous deﬁcient females, and 0.5*2*qG6PD*(1− qG6PD)= 6.9% are G6PD
heterozygous deﬁcient females. We assumed that 5% of the population had a low
CYP2D6 metabolizer phenotype, where primaquine was not efﬁcacious, but that
tafenoquine retained its efﬁcacy56. Assuming the availability of treatment and
G6PD testing, this leads to an effectiveness at clearing hypnozoites of 55.3% for
primaquine and 83.2% for tafenoquine.
Intervention models: vector control. An existing model of the effects of LLINs on
the behaviour of Anopheles mosquitoes was incorporated into the model50,57. We
assume that LLINs have three effects on adult mosquitoes: (i) killing mosquitoes
that land on nets; (ii) repelling and possibly diverting mosquitoes to an animal
blood host due to either insecticide irritation or the physical barrier of the net; and
(iii) lengthening the duration of the gonotrophic cycle leading to a reduced ovi-
position rate. This model was parameterised to reﬂect the behaviour of the three
primary malaria vectors in PNG: An. farauti s. s., An. koliensis and An. punctu-
latus53. The metric of LLIN coverage employed here is based on use: the proportion
of individuals who slept under an LLIN last night58. A critical parameter for the
effectiveness of LLIN campaigns is the duration of LLIN usage. We assumed that
loss of adherence to LLINs occurs at a constant rate so that 50% are still being used
after 19.5 months based on data on the age distribution of nets collected in PNG59.
This duration is shorter than in African data where it was estimated that 50% of
LLINs are lost after 23 (20–28) months32, and also shorter than older recom-
mended assumptions of 36 months from the Roll Back Malaria Harmonization
Working Group33. Additional sensitivity analyses with these longer durations were
simulated.
Application to PNG. In 2004 PNG received a grant from The Global Fund to Fight
AIDS, Tuberculosis and Malaria to initiate country-wide free distribution of LLINs.
This led to large increases in LLIN ownership with 64.6% of households owning a
net by 200912. In our study we deﬁne LLIN coverage according to LLIN use—the
proportion of individuals surveyed who slept under a LLIN during the previous
night. Data on coverage are informed by use surveys12, and distribution data from
Rotarians Against Malaria—the organisation responsible for nationwide distribu-
tion campaigns. The key metric of P. vivax transmission intensity is prevalence by
light microscopy (PvPRLM). Transmission intensity in each province was measured
via household prevalence surveys in at least two randomly selected villages from
each province6. These surveys were supplemented by measurements from a
selection of sentinel sites before LLIN distribution and surveys taken shortly after
LLIN distribution13. Maps of PNG provinces were generated in R using shape ﬁles
from http://otlet.sims.berkeley.edu/imls/world/PNG/. In each province P. vivax
transmission was simulated using the individual-based model. To explore the
potential role of inter-provincial travel, we performed a sensitivity analysis where
all provinces were simulated simultaneously, accounting for travel of people
between provinces by air, road and sea (see Supplementary Information section on
inter-provincial travel in PNG).
Data availability. The C++ code for implementation of the individual-based
model, the model for inter-provincial travel and the data used for model calibration
is available for download from GitHub @MWhite-InstitutPasteur (https://github.
com/MWhite-InstitutPasteur/Pvivax_IBM).
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Fig. 6 Compartmental representation of P. vivax transmission model in
humans. Infected individuals can be in one of three compartments
depending on whether blood-stage parasitaemia is detectable by PCR
(IPCR), light microscopy (ILM) or has high density with accompanying fever
(ID). A proportion of individuals that progress to a symptomatic episode of
P. vivax will undergo treatment with a blood-stage drug (T) leading to
clearance of blood-stage parasitaemia and a period of prophylactic
protection (P) before returning to the susceptible state (S). The superscript
k denotes the number of batches of relapse causing hypnozoites in the liver.
Red arrows denote new blood-stage infections arising from either new
mosquito bites or relapses. Each square denotes a compartment and the
circles denote the dependence of transition rates between compartments
on levels of anti-parasite immunity (Ap) and levels of clinical immunity (Ac)
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